Akebia Therapeutics Inc (AKBA) Unusual Options Activity Today

Checking AKBA unusual options activity helps you spot when traders are making outsized bets on Akebia Therapeutics Inc before the broader market catches on. Akebia Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor AKBA unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching AKBA unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking AKBA unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and AKBA unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.

Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Catalysts rarely arrive without a footprint, and AKBA unusual options activity is often where that footprint shows up first. Our scanner tracks Akebia Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at AKBA unusual options volume on the call side or chasing put sweeps, Akebia Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.